MA24512A1 - Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose - Google Patents

Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Info

Publication number
MA24512A1
MA24512A1 MA24467A MA24467A MA24512A1 MA 24512 A1 MA24512 A1 MA 24512A1 MA 24467 A MA24467 A MA 24467A MA 24467 A MA24467 A MA 24467A MA 24512 A1 MA24512 A1 MA 24512A1
Authority
MA
Morocco
Prior art keywords
thrombosis
preparation
treatment
agents useful
anticoagulating agents
Prior art date
Application number
MA24467A
Other languages
English (en)
Inventor
Neal Blackburn Michael
Robert Church William
Zeev Feuerstein Giora
Stuart Gross Mitchell
John Nichols Andrew
Agustin Padlan Eduardo
Haribhai Patel Arunbhai
Robert Sylvester Daniel
Original Assignee
Univ Vermont And State Agrienl
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vermont And State Agrienl, Smithkline Beecham Corp filed Critical Univ Vermont And State Agrienl
Publication of MA24512A1 publication Critical patent/MA24512A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA24467A 1996-01-17 1997-01-15 Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose MA24512A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1010896P 1996-01-17 1996-01-17
US2911996P 1996-10-24 1996-10-24

Publications (1)

Publication Number Publication Date
MA24512A1 true MA24512A1 (fr) 1998-12-31

Family

ID=26680794

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24467A MA24512A1 (fr) 1996-01-17 1997-01-15 Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Country Status (25)

Country Link
US (5) US6005091A (fr)
EP (2) EP1832297A1 (fr)
JP (2) JP2000503210A (fr)
KR (1) KR100553629B1 (fr)
CN (1) CN1213312A (fr)
AR (1) AR005658A1 (fr)
AT (1) ATE330630T1 (fr)
AU (1) AU706397B2 (fr)
BR (1) BR9707049A (fr)
CZ (1) CZ299452B6 (fr)
DE (1) DE69736197T2 (fr)
DK (1) DK1007089T3 (fr)
ES (1) ES2267131T3 (fr)
HU (1) HU225903B1 (fr)
ID (1) ID17156A (fr)
IL (1) IL125380A0 (fr)
MA (1) MA24512A1 (fr)
MX (1) MX9805810A (fr)
NO (1) NO983284L (fr)
NZ (2) NZ331014A (fr)
PL (1) PL187274B1 (fr)
PT (1) PT1007089E (fr)
SI (1) SI1007089T1 (fr)
TR (1) TR199801390T2 (fr)
WO (1) WO1997026010A1 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20040038898A1 (en) * 1996-05-16 2004-02-26 The Trustees Of Columbia University Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
EP1001991A4 (fr) * 1997-07-03 2005-01-26 Smithkline Beecham Corp Structures cristallines de fragments fab anti-facteur ix et procedes d'utilisation pour la conception de peptidomimetique
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
AU760678B2 (en) * 1998-05-08 2003-05-22 Stichting Sanquin Bloedvoorziening Method for diagnosis and treatment of haemophilia a patients with an inhibitor
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
WO2000007626A1 (fr) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Utilisation d'anticorps de facteur anticoagulant comme agents protecteurs longue duree
ES2177316T3 (es) 1998-08-28 2002-12-01 Genentech Inc Anticuerpos humanos antifacotores ix/ixa.
WO2000026394A1 (fr) * 1998-10-31 2000-05-11 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Variants de l'anticorps monoclonal anti-carcinome de type humain cc49
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7829085B2 (en) * 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
JP4297207B2 (ja) * 1999-07-14 2009-07-15 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルク 止血障害処置のための治療組成物に使用するためのリガンド
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
EP1825864A3 (fr) * 2000-05-15 2007-09-12 SmithKline Beecham Corporation Agents antithrombotiques
WO2002026932A2 (fr) * 2000-09-26 2002-04-04 Duke University Aptameres d'arn et procede d'identification desdits aptameres
DK1222929T3 (da) 2001-01-11 2010-09-06 Life Sciences Res Partners Vzw Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom
CA2441228A1 (fr) * 2001-03-23 2002-10-03 Aphton Corporation Traitement combine du cancer du pancreas
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2002313194B9 (en) * 2001-06-12 2008-06-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor VIII antibody
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
US20080219998A1 (en) * 2001-12-07 2008-09-11 Andras Gruber Anti-Thrombotic Agents
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
EP1532162B1 (fr) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme
US6928528B1 (en) 2002-10-07 2005-08-09 Advanced Micro Devices, Inc. Guaranteed data synchronization
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
US7235376B2 (en) * 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
CA2535489C (fr) 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Anticorps permettant de lutter contre le facteur viii avec glycosylationmodifiee dans la region variable
WO2005021594A2 (fr) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Variants a peine immunogenes de l'anticorps humanise a greffe sdr cc49 et leur utilisation
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) * 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP2567974A3 (fr) 2004-09-22 2013-05-22 Cancer Advances, Inc., Anticorps monoclonaux contre la progastrine
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP4793360A2 (fr) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Procédés de régulation de la pharmacocinétique sanguine d'anticorps
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
WO2008067056A2 (fr) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Procédé d'inhibition de la coagulation avec des anticorps anti-facteur va humains et utilisation de ceux-ci
EP2527369A3 (fr) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Anticorps monoclonal anti-bêta-amyloide (abêta) et ses utilisations
EP2197914A1 (fr) 2007-09-13 2010-06-23 Delenex Therapeutics AG Anticorps humanisés contre le peptide bêta-amyloïde
EP3127921A1 (fr) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
WO2009049234A2 (fr) * 2007-10-11 2009-04-16 Regents Of The University Of California Procédés de traitement d'une coagulopathie
WO2009154461A1 (fr) * 2008-06-19 2009-12-23 Prothix Bv Utilisation d’anticorps anti-facteurs xi pour prévenir la formation de thrombus
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
WO2014100740A1 (fr) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anticorps anti-ntb-a et compositions et procédés associés
WO2014160088A2 (fr) * 2013-03-14 2014-10-02 Rhode Island Hospital, A Lifespan-Partner Traitement d'infections par le virus de l'hépatite b
CA2925256C (fr) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Procede de production d'un heteromultimere polypeptidique
EA201790336A1 (ru) 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JOP20160131B1 (ar) 2015-06-26 2022-03-14 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3325516B1 (fr) * 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited Anticorps monoclonal inhibiteur, dirigé contre le facteur xiia
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EA201892716A1 (ru) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
CA3027018A1 (fr) 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps bispecifique presentant une activite de fonction alternative accrue du cofacteur fviii
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
AU2017363309A1 (en) * 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
IL271427B2 (en) 2017-06-15 2025-08-01 Cancer Advances Inc Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CA3071236A1 (fr) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Molecule multispecifique de liaison a l'antigene ayant une activite de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molecule en tant que principe actif
KR20260090008A (ko) 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
TWI772724B (zh) 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2049655C (fr) * 1990-09-17 1996-11-12 Akio Odawara Composition pharmaceutique pour inhiber l'aggregation des plaquettes
WO1993009804A1 (fr) * 1991-11-18 1993-05-27 The Scripps Research Institute Polypeptides derives de la serine protease et anticorps anti-peptidiques, systemes et procedes therapeutiques empechant la coagulation du sang
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
DK0658168T3 (da) * 1992-08-27 2001-01-22 Sanquin Bloedvoorziening Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
US5397581A (en) * 1993-02-05 1995-03-14 Lerman; Russell E. Means for continuous confectionery coating of edible centers
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents

Also Published As

Publication number Publication date
US20020146411A1 (en) 2002-10-10
EP1832297A1 (fr) 2007-09-12
CZ222598A3 (cs) 2000-01-12
EP1007089B1 (fr) 2006-06-21
US20070003553A1 (en) 2007-01-04
ATE330630T1 (de) 2006-07-15
HK1029513A1 (en) 2001-04-06
EP1007089A4 (fr) 2003-04-16
CZ299452B6 (cs) 2008-07-30
TR199801390T2 (xx) 1998-12-21
JP2007325602A (ja) 2007-12-20
SI1007089T1 (sl) 2006-12-31
DE69736197D1 (de) 2006-08-03
PL187274B1 (pl) 2004-06-30
EP1007089A1 (fr) 2000-06-14
KR19990077329A (ko) 1999-10-25
US6005091A (en) 1999-12-21
NZ331014A (en) 2000-01-28
US6391299B1 (en) 2002-05-21
KR100553629B1 (ko) 2006-10-04
NO983284L (no) 1998-09-16
PL327929A1 (en) 1999-01-04
AU1830897A (en) 1997-08-11
HU225903B1 (en) 2007-12-28
US20070224198A1 (en) 2007-09-27
NZ501215A (en) 2001-04-27
WO1997026010A1 (fr) 1997-07-24
CN1213312A (zh) 1999-04-07
AR005658A1 (es) 1999-07-14
MX9805810A (es) 1998-11-30
IL125380A0 (en) 1999-03-12
HUP9900396A2 (hu) 1999-05-28
AU706397B2 (en) 1999-06-17
HUP9900396A3 (en) 2001-10-29
ES2267131T3 (es) 2007-03-01
PT1007089E (pt) 2006-11-30
DK1007089T3 (da) 2006-10-09
DE69736197T2 (de) 2007-06-21
NO983284D0 (no) 1998-07-16
JP2000503210A (ja) 2000-03-21
ID17156A (id) 1997-12-04
BR9707049A (pt) 2000-10-24

Similar Documents

Publication Publication Date Title
EP1007089A4 (fr) Agents coagulants utiles dans le traitement de la thrombose
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
FR2715405B1 (fr) Procédé pour l'élimination des prions dans des collagènes et collagènes ainsi obtenus.
EP1014982A4 (fr) Composes de troglitazone pour le traitement de l'age critique
FR2767604B1 (fr) Procede de traitement pour le collage moleculaire et le decollage de deux structures
FR2737654B1 (fr) Unite de filtration pour la retenue de caillots sanguins
EP1007048A4 (fr) Identification d'agents utiles dans le traitement de la maladie d'alzheimer
EP0754042A4 (fr) Traitement de l'atherosclerose
EP0810860A4 (fr) Procede et utilisation du radicicol pour le traitement de l'inflammation et de l'endotoxemie
EP0892599A4 (fr) Procede d'elimination de psoralenes dans des fluides biologiques
FR2666621B1 (fr) Produit et procede pour la diversion d'acide dans le traitement de formations souterraines.
FR2542495B1 (fr) Procede pour l'incorporation de boues dans du cimentÿa
EP0861082A4 (fr) Traitement de l'insuffisance de la membrane tissulaire
MA24332A1 (fr) Utilisation de 1-hydroxy-2- pyridones pour le traitement d'infections de la peau
DE69033413D1 (de) Mittel zur Behandlung von Metalloberflächen
EP1131735A4 (fr) Systeme de molecules intelligentes pour le traitement d'information reseau dans n'importe quel objet physique
FR2744648B1 (fr) Procede de preparation d'agents tensioactifs
FR2758465B1 (fr) Composition pour le traitement de l'amiante
EP0860867A4 (fr) Traitement de surface pour micro-usinage
FR2747398B1 (fr) Procede de traitement de surface d'une piece metallique
FR2728142B1 (fr) Composition pour le traitement anti-germinatif de tubercules ou de bulbes ; procede de traitement
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
EP0859761A4 (fr) 4-azasteroides utilises pour le traitement d'etats hyperandrogeniques
EP0755255A4 (fr) Traitement de la toxoplasmose
EP0840605A4 (fr) Composes utiles dans le traitement des neurofibromatoses